Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon Therapy for EPI in Pancreatic Cancer
NCT03859869Phase 4Terminated
- Sponsor
- AbbVie Inc.
- Start
- Feb 2020
- Primary completion
- Mar 2022
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of pancrelipase in exocrine pancreatic insufficiency (EPI), sponsored by AbbVie Inc.. Started Feb 2020; status: terminated.
02
Drugs
pancrelipase
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT03859869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03859869.